Targacept Unveils Depression Drug Data Next Week: BioBuzz
This is the commercial opportunity that Targacept is shooting for with TC-5214. And Targacept's drug could be an even bigger hit because its tolerability and side effect profile are likely to be superior to Abilify.
Targcept is currently seeking a large pharmaceutical partner for TC-524, which makes next week's data presentation even more important. Plans for phase III studies are underway.
"I think there is a lot of Big Pharma interest in this drug," said the aforementioned hedge fund analyst.
The danger with a high-flying stock like Targacept is that investor expectations run well ahead of the actual event, so when the data do come out (and even if they look good) investors take quick profits."With an effect size of two points or higher on the HAM-D and a clean safety profile, I think Targacept can ultimately be a $30-plus stock," said the analyst, who again, owns the stock. But will Targacept see $30 soon after the Oct. 15 data presentation? Or, will the appreciation come only after a profit-taking dip in the stock price? My bullish Targacept analyst didn't know the answer to that question, unfortunately. Update: Targacept closed this morning on a spot offering of 2.2 million shares at $21 a share. At that price, the offering grosses $46 million. Why raise money now? Should this be a concern with the TC-5214 data presentation next week? I'm told the company wanted to take advantage of the recent strength in its stock price to bolster the balance sheet. Investor demand for the offering was high. "This doesn't worry me at all, " said my bullish Targacept analyst. "We are not selling." Targacept shares are down 11% to $20 in pre-market trading.
Research Firm: Geron's Stem-Cell Drug Has Safety ProblemsIndependent healthcare research shop SummerStreet Research Partners issued another bearish assessment Wednesday of Geron (GERN) and its stem cell treatment for spinal cord injury. Recall that FDA placed Geron's spinal cord trial on a clinical hold in August due to the discovery of non-cancerous cysts in the spinal cords of animals treated with the stem cells.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV